San Carlos, Calif. (May 31, 2005) – Conceptus, Inc. (Nasdaq: CPTS), developer of the non-incisional permanent birth control procedure Essure®, today announced that it has accepted an invitation to present at Pacific Growth Equities 2005 Life Sciences Growth Conference on Monday June 6, 2005. Greg Lichtwardt, Conceptus’ chief financial officer will present at 4:30 PM PST. The conference will be held at the InterContinental Mark Hopkins Hotel in San Francisco from June 6 through June 8, 2005.
The conference is an exclusive gathering of leading technology and life science company CEOs and institutional portfolio managers. During the three-day event, investors will have access to over 120 leading public and private companies in technology and life sciences. More information about Pacific Growth Equities Life Sciences Growth Conference can be found at
www.pacificgrowth.com.
About Conceptus
Conceptus, Inc. manufactures and markets Essure, an innovative medical device and procedure, designed to provide a non-incisional alternative to tubal ligation, which is the leading form of birth control worldwide. The availability of Essure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually.
Additional information about the
Essure procedure is available at
www.essure.com or by calling the
Essure Information line at 1-877-ESSURE1. Additional information about Conceptus is available at
www.conceptus.com or by calling 1-877-ESSURE2.
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. FDA approvals on 4 and 5 year effectiveness, post approval study for placement rates, comparisons to surgical alternatives, the effect of these items on commercialization efforts, and the worldwide market for permanent birth control, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors such as strategic planning decisions by management, re-allocation of internal resources, decisions by insurance companies, delays by regulatory authorities, scientific advances by third parties, and introduction of competitive products, as well as those factors set forth in the Company's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, and other filings with the Securities and Exchange Commission.
